Found 7 matching trials
Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906) PHASE1 This is a multicenter, interventional, non-randomized study among patients ...
Show More Location
CHU Amiens Picardie
Learn More & Join Trial
Fentanyl Background Infusion for Acute Postoperative Pain NA We investigated the efficacy and the safety of the pharmacokinetic model-ba...
Show More Location
Ajou University School of Medicine
Learn More & Join Trial
Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies. PHASE3 The aim of the study was to evaluate efficacy and tolerability of Thalidomi...
Show More Location
CHU CAEN Dept of Hematology
Learn More & Join Trial
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil N/A In this project, the investigators intend to start a prospective registry f...
Show More Location
Instituto do Cancer do Estado de Sao Paulo
Learn More & Join Trial
The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT PHASE2 The purpose of this study is to determine whether Intensity-modulated radia...
Show More Location
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Learn More & Join Trial
Short RT Versus RCT,Followed by Chemo and Organ Preservation for Interm and High-risk Rectal Cancer Patients PHASE3 The hereby proposed ACO/ARO/AIO-18.1 randomized trial aims to directly comp...
Show More Status
Active Not Recruiting
Location
Clincal Center Esslingen
Treatments Being Tested
Oxaliplatin, 85 mg/m2 5FU; 2400 mg/m2 5FU, 250 mg/m2 5FU, 2400 mg/m2 Oxaliplatin 50 mg/m2 Folinic Acid, 400 mg/m2 Radiotherapy control, 5x5 Gy: 25 Gy Capecitabine, 1000 mg/m2 Oxaliplatin 85 mg/m2 radiotherapy experimental, 30 x 1,8 Gy: 54 Gy Capecitabine, 825 mg/m2 Oxaliplatin, 130 mg/m2 Learn More & Join Trial
Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB PHASE2 This study is designed as a single arm, un-controlled, open-label, multi-ce...
Show More Learn More & Join Trial